Level B· Emerging clinical evidence with positive signalsRandomized Controlled TrialPubMedOpen access

Safety profile of autologous adipose-derived stromal vascular fraction in clinical use: an exhaustive literature review.

Nonnarath C., Serratrice N.

Randomized Controlled Trial on Systemic / IV, published in Stem Cell Res Ther (2026) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Stem Cell Res Ther (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41618435
PMCID
PMC12933908
DOI
10.1186/s13287-026-04909-6
Citations
3

Abstract (original English)

Adipose tissue-derived stromal vascular fraction (SVF) has rapidly emerged as a promising tool in regenerative medicine due to its accessibility, autologous origin, and potent reparative potential. However, despite encouraging preclinical outcomes, the clinical safety of SVF across organ systems remains insufficiently characterized. This comprehensive review synthesizes current evidence on the safety and tolerability of autologous SVF therapy in humans, organized by target organ systems including cardiovascular, pulmonary, hepatic, renal, musculoskeletal, cutaneous, neurological, and inflammatory applications. Across studies, SVF therapy appears technically feasible and generally well tolerated, with adverse events predominantly mild and procedure-related (e.g., transient pain, swelling, or local inflammation). Serious complications - including embolism, infection, fibrosis, or tumor formation - have not been reported to date in clinical settings. However, available studies suffer from major limitations: small and heterogeneous cohorts, non-randomized designs, variability in cell preparation and dosing, and short follow-up durations. The lack of standardized isolation protocols and absence of mechanistic endpoints further restrict interpretation. Overall, current data support the short-term safety of autologous SVF therapy, while underscoring the need for large-scale randomized

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research